Report of Foreign Issuer (6-k)
March 11 2015 - 9:19AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March, 2015
Commission File Number
Novogen
Limited
(Translation of registrants name into English)
16-20 Edgeworth David Ave, Hornsby, NSW 2077, Australia
(Address of principal executive office)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F þ Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): ¨
Note: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrants home country), or under the rules of the home country exchange on which the registrants securities are traded, as long as the report or other document is not a press release, is
not required to be and has not been distributed to the registrants security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission
pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes ¨ No þ
If yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
Novogen Limited (Registrant)
Lionel Mateo
Lionel Mateo
Company Secretary
Date 11 March 2015
|
|
|
NOVOGEN LIMITED ASX:
NRT |
|
|
(NASDAQ: NVGN)
11 March 2015
ISSUE OF UNLISTED OPTIONS
Novogen Limited (ASX:NRT NASDAQ:NVGN) advises that 48,776,832 unlisted Options (Options) were issued on Tuesday 10 March 2015,
following the approval of its Shareholders at a General Meeting held on Wednesday 4 March 2015, to 3 US investors and the placement agent.
On 16 and
18 December 2014, the Company issued respectively 32,850,000 and 14,050,800 (total 46,900,800) ordinary shares to 3 US investors.
The placement
agent received the entitlement of 4% option coverage for each placement.
The Options were issued in two different tranches (referred to as Tranche
A and Tranche B below) in order to match the each placement date.
The details of the Options are set out in the table below:
|
|
|
|
|
TRANCHE A |
|
US Investors |
|
Placement Agent (4%) |
Unlisted Options |
|
32,850,000 |
|
1,314,000 |
Exercise Price |
|
15 cents ($0.15) |
Expiry Date |
|
16 December 2019 |
Underlying Security |
|
Ordinary Shares Ranking pari passu with existing ordinary shares |
|
|
|
|
|
TRANCHE B |
|
US Investors |
|
Placement Agent (4%) |
Unlisted Options |
|
14,050,800 |
|
562,032 |
Exercise Price |
|
15 cents ($0.15) |
Expiry Date |
|
18 December 2019 |
Underlying Security |
|
Ordinary Shares Ranking pari passu with existing ordinary shares |
The total number of Options issued is 48,776,832.
For more information, please contact:
Lionel
Mateo
Company Secretary
Novogen Limited
Lionel.Mateo@novogen.com
+61 2 9472 4100
NOVOGEN LTD ACN 063 259 754
16-20 Edgeworth David Ave, Hornsby, NSW, 2077 | P: +61 (0) 2 9472 4100 - F: +61 (0) 2 9476 0388 | www.novogen.com
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024